CCS adapting to COVID-19 realities to support Canadians during and after the pandemic
Dr Ming-Sound Tsao
O. Harold Warwick Prize recipient in 2011
Dr Ming-Sound Tsao’s research has significantly advanced the understanding and use of molecular information to improve the treatment of lung cancer. His research team was among the first to define molecular markers that may be used in selection of patients for new targeted anti-cancer drugs. His team has also identified gene signatures that may predict outcome for patients with early stage non-small cell lung cancer, and may identify patients who may benefit from post-surgery chemotherapy. He has made significant contributions to international collaborative efforts in the molecular characterization of lung cancer.
Dr Tsao is a long-standing contributor to lung cancer clinical trials in Canada led by the Canadian Cancer Trials Group (CCTG). His leadership in the molecular analyses of tumour samples from several seminal CCTG trials has established Canada as a global leader in lung cancer research. He has also led several efforts to institute and standardize molecular testing in lung cancer across Canada.
Dr Tsao is a pathologist-scientist at the University Health Network (UHN) in Toronto where he holds the Qasim Choksi Chair in Lung Cancer Translational Research. He is a senior scientist at the Ontario Cancer Institute and professor of laboratory medicine and pathobiology at the University of Toronto. He co-chairs the CCTG Correlative Science Tumour Biology Committee. He is also the Chair of the Pathology Committee of the International Association for Study of Lung Cancer(IASLC).
Dr Tsao is recognized globally as a leading lung cancer molecular pathologist. He has published close to 300 scientific papers in highly ranked peer-reviewed journals, including The New England Journal of Medicine and Nature. Dr Tsao has been a generous contributor to the peer-review system in Canada, and is an outstanding teacher and mentor, dedicated to training the next generation of pathologists and clinicians in molecular and translational research.
Investing to reduce cancer burden
Last year CCS funded $40 million in cancer research, thanks to our donors. Discover how you can help reduce the burden of cancer.